SCHEMBL1961365

SCHEMBL1961365

O=c1cc(O)oc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
USP2 O75604 1/20 0.59
CSNK2A2 P19784 1/20 0.59
PTGS1 P23219 1/20 0.59
CSNK2B P67870 1/20 0.59
CSNK2A1 P68400 1/20 0.59
CSNK2A3 Q8NEV1 1/20 0.59
TNKS O95271 6/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
BCHE P06276 1/20 0.59
POLB P06746 1/20 0.59
ACHE P22303 1/20 0.59
AKR1C3 P42330 1/20 0.59
AKR1C2 P52895 1/20 0.59
AKR1C1 Q04828 1/20 0.59
FTO Q9C0B1 2/20 0.57
HPGD P15428 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29966031 1.00 KDM4E (0.59) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL2483048 0.76 KDM4E (0.56) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL30503392 0.76 KDM4E (0.56) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL31622431 0.76 TNKS (0.53) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL31622430 0.76 TNKS (0.53) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL24969553 0.75 TNKS (0.59) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL1943194 0.75 KDM4E (0.59) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL123427 0.75 TNKS (0.59) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL3456369 0.75 TNKS (0.56) KDM4EUSP2CSNK2A2PTGS1CSNK2B
SCHEMBL294054 0.75 TNKS (0.56) KDM4EUSP2CSNK2A2PTGS1CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
CN-118086421-A Application of agilawood endophyte in catalyzing chromone to produce hydroxychromone 中国科学院昆明植物研究所 2024-05-28 CN claimed
EP-4157811-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS McMaster University (CA) 2023-04-05 EP claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021237371-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS MCMASTER UNIVERSITY (CA) 2021-12-02 WO claimed
CN-110496163-A The preparation method of citrous bud or flower or branch or leaf or fruit active component or ingredient and its application in medicine preparation UNIV JIANGXI TRADITIONAL CHINESE MEDICINE 2019-11-26 CN claimed
CN-110064002-A Flores aurantii and branches and leaves active component or ingredient improve sleep or antidepression in preparation or improve the application in failure of memory drug or food 江西中医药大学 2019-07-30 CN claimed
CN-109745384-A The application and preparation method thereof of bitter orange flower active component or effective component in preparation treatment cardio-cerebrovascular ischemic disease drug 江西中医药大学 2019-05-14 CN claimed
WO-2013013901-A1 PROCESS FOR TREATING HUMAN PERSPIRATION USING POLYPHENOLS AND AN ENZYMATIC AND/OR CHEMICAL CATALYTIC OXIDATION SYSTEM L'OREAL (FR) 2013-01-31 WO claimed
WO-2011073941-A1 USE OF A POLYMER AS AN ANTIOXIDANT AGENT L'OREAL (FR) 2011-06-23 WO claimed
EP-1352635-A2 Composition for dyeing keratinous fibres comprising a system which restricts the transcutaneous passage of an oxidation dye L'OREAL (FR) 2003-10-15 EP claimed
EP-1348421-A2 A method of thickening and styling human keratinous fibres using a particular catalytic system L'OREAL (FR) 2003-10-01 EP claimed
US-20030163878-A1 Dyeing composition, method for obtaining the same and use for colouring the skin and/or keratinous fibres L'OREAL (FR) 2003-09-04 US claimed
US-20030103917-A1 Dyeing composition promoting natural pigmentation, method for obtaining same and use for colouring the skin and/or keratinous fibres L'OREAL (FR) 2003-06-05 US claimed
US-20020124330-A1 Coloration composition, process for obtaining the same and its use for the coloration of keratin fibres L'OREAL (FR) 2002-09-12 US claimed
EP-1229892-A1 DYEING COMPOSITION, METHOD FOR OBTAINING SAME AND USE FOR COLOURING THE SKIN AND/OR KERATINOUS FIBRES L'OREAL (FR) 2002-08-14 EP claimed
EP-1229890-A1 DYEING COMPOSITION PROMOTING NATURAL PIGMENTATION, METHOD FOR OBTAINING SAME AND USE FOR COLOURING THE SKIN AND/OR KERATINOUS FIBRES L'OREAL (FR) 2002-08-14 EP claimed
EP-1210931-A1 Keratinic fibres dyeing composition L'OREAL (FR) 2002-06-05 EP claimed
WO-2002030371-A1 DYEING COMPOSITION PROMOTING NATURAL PIGMENTATION, METHOD FOR OBTAINING SAME AND USE FOR COLOURING THE SKIN AND/OR KERATINOUS FIBRES L"OREAL (FR) 2002-04-18 WO claimed
WO-2002030375-A1 DYEING COMPOSITION, METHOD FOR OBTAINING SAME AND USE FOR COLOURING THE SKIN AND/OR KERATINOUS FIBRES L"OREAL (FR) 2002-04-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030103917-A1 Dyeing composition promoting natural pigmentation, method for obtaining same and use for colouring the skin and/or keratinous fibres TYR, KRT18, POLR1C KDM4E 3480/4885USP2 3218/4885CSNK2A2 610/4885
US-20030163878-A1 Dyeing composition, method for obtaining the same and use for colouring the skin and/or keratinous fibres KRT18, HAO2, TYR KDM4E 2350/4885USP2 2799/4885CSNK2A2 308/4885
US-20020124330-A1 Coloration composition, process for obtaining the same and its use for the coloration of keratin fibres KRT18, TYR, OAT KDM4E 611/4885USP2 2668/4885CSNK2A2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.